Patient Portal

Marin H. Kollef, MD, FACP, FCCP

Professor, Medicine
Division of Pulmonary and Critical Care Medicine
Director, Medical Intensive Care Unit, Barnes-Jewish Hospital
Director, Respiratory Care Services, Barnes-Jewish Hospital

Specialty Areas

Pulmonary Disease
Critical Care Medicine

Board Certifications

Pulmonary Disease
Internal Medicine
Critical Care Medicine

Hospital Affiliations

Barnes-Jewish Hospital

Referral Information

Professional Consultation Only

Areas of Clinical Interest

Critical care medicine, pneumonia, emphysema,

  • Location(s)
  • Education
  • Publication & Research
  • Financial Disclosures

Location(s)

Location(s)

Barnes-Jewish Hospital

1 Barnes-Jewish Hospital Plaza
St. Louis, MO 63110

Education

Education

Fellowship: Fred Hutchinson Cancer Institute, Seattle, Washington; Bone Marrow Transplant Critical Care Service 1988
Fellowship: Pulmonary Disease and Critical Care, Madigan Army Medical Center, Tacoma, Washington 1988
Residency: Internal Medicine, Madigan Army Medical Center, Tacoma, Washington 1986
Medical Degree: University Of Rochester, Rochester, New York 1983

Publication & Research

Publication & Research

Protocol for a prospective, observational cohort study of awareness in mechanically ventilated patients admitted from the emergency department: the ED-AWARENESS study.
Pappal RD, Roberts BW, Mohr NM, Ablordeppey E, Wessman BT, Drewry AM, Yan Y, Kollef MH, Avidan MS, Fuller BM
BMJ Open. 2019 Oct 7; 9(10)e033379. doi: 10.1136/bmjopen-2019-033379.

PMID:
    31594905
    [PubMed - in process]
Related citations


Novel Approaches to Hasten Detection of Pathogens and Antimicrobial Resistance in the Intensive Care Unit.
Guillamet MCV, Burnham JP, Kollef MH
Semin Respir Crit Care Med. 2019 Aug; 40(4)454-464. doi: 10.1055/s-0039-1693160.

PMID:
    31585472
    [PubMed - in process]
Related citations


Ceftolozane-tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial.
Kollef MH, Nováček M, Kivistik Ü, Réa-Neto Á, Shime N, Martin-Loeches I, Timsit JF, Wunderink RG, Bruno CJ, Huntington JA, Lin G, Yu B, Butterton JR, Rhee EG
Lancet Infect Dis. 2019 Sep 25; pii: S1473-3099(19)30403-7. doi: 10.1016/S1473-3099(19)30403-7.

PMID:
    31563344
    [PubMed - as supplied by publisher]
Related citations


The ED-SED Study: A Multicenter, Prospective Cohort Study of Practice Patterns and Clinical Outcomes Associated With Emergency Department SEDation for Mechanically Ventilated Patients.
Fuller BM, Roberts BW, Mohr NM, Knight WA 4th, Adeoye O, Pappal RD, Marshall S, Alunday R, Dettmer M, Goyal M, Gibson C, Levine BJ, Gardner-Gray JM, Mosier J, Dargin J, Mackay F, Johnson NJ, Lokhandwala S, Hough CL, Tonna JE, Tsolinas R, Lin F, Qasim ZA, Harvey CE, Bassin B, Stephens RJ, Yan Y, Carpenter CR, Kollef MH, Avidan MS
Crit Care Med. 2019 Nov; 47(11)1539-1548. doi: 10.1097/CCM.0000000000003928.

PMID:
    31393323
    [PubMed - in process]
Related citations


Moving the Practice of Respiratory Therapy Forward.
Kollef MH, Watts P
Respir Care. 2019 Aug; 64(8)1014-1016. doi: 10.4187/respcare.07017.

PMID:
    31346076
    [PubMed - in process]
Related citations


Factors Associated With Clinical Deterioration Among Patients Hospitalized on the Wards at a Tertiary Cancer Hospital.
Lyons PG, Klaus J, McEvoy CA, Westervelt P, Gage BF, Kollef MH
J Oncol Pract. 2019 Aug; 15(8)e652-e665. doi: 10.1200/JOP.18.00765.

PMID:
    31306039
    [PubMed - in process]
Related citations


Vancomycin/Pipiercillin-Tazobactam Nephrotoxicity in the Critically Ill.
Kollef MH, Juang P, Micek ST
Clin Infect Dis. 2019 Jul 11; pii: ciz643. doi: 10.1093/cid/ciz643.

PMID:
    31297504
    [PubMed - as supplied by publisher]
Related citations


Cluster analysis to define distinct clinical phenotypes among septic patients with bloodstream infections.
Guilamet MCV, Bernauer M, Micek ST, Kollef MH
Medicine (Baltimore). 2019 Apr; 98(16)e15276. doi: 10.1097/MD.0000000000015276.

PMID:
    31008972
    [PubMed - indexed for MEDLINE]
Related citations


Rebuttal From Drs Aguilar and Kollef.
Aguilar PR, Kollef MH
Chest. 2019 Apr; 155(4)668-669. doi: 10.1016/j.chest.2018.11.017.

PMID:
    30955570
    [PubMed - in process]
Related citations


POINT: Does Persistent or Worsening ARDS Refractory to Optimized Ventilation and Proning Deserve a Trial of Prostacyclin? Yes.
Aguilar PR, Kollef MH
Chest. 2019 Apr; 155(4)662-665. doi: 10.1016/j.chest.2018.11.018.

PMID:
    30955568
    [PubMed - in process]
Related citations


Reduction in antimicrobial use among medical intensive care unit patients during a cluster randomized crossover trial of palliative care consultation.
Burnham JP, Chi S, Ma J, Dans MC, Kollef MH
Infect Control Hosp Epidemiol. 2019 Apr; 40(4)491-492. doi: 10.1017/ice.2019.34.

PMID:
    30838966
    [PubMed - in process]
Related citations


New antibiotics for community-acquired pneumonia.
Kollef MH, Betthauser KD
Curr Opin Infect Dis. 2019 Apr; 32(2)169-175. doi: 10.1097/QCO.0000000000000526.

PMID:
    30640820
    [PubMed - in process]
Related citations


Outcomes Associated With De-escalating Therapy for Methicillin-Resistant Staphylococcus aureus in Culture-Negative Nosocomial Pneumonia.
Cowley MC, Ritchie DJ, Hampton N, Kollef MH, Micek ST
Chest. 2019 Jan; 155(1)53-59. doi: 10.1016/j.chest.2018.10.014.

PMID:
    30621854
    [PubMed - indexed for MEDLINE]
Related citations


Antibiotic Thresholds for Sepsis and Septic Shock.
Kollef MH, Burnham JP
Clin Infect Dis. 2019 Aug 30; 69(6)938-940. doi: 10.1093/cid/ciy1035.

PMID:
    30535353
    [PubMed - in process]
Related citations


Duration of Exposure to Antipseudomonal β-Lactam Antibiotics in the Critically Ill and Development of New Resistance.
Teshome BF, Vouri SM, Hampton N, Kollef MH, Micek ST
Pharmacotherapy. 2019 Mar; 39(3)261-270. doi: 10.1002/phar.2201.

PMID:
    30506852
    [PubMed - in process]
Related citations


The carbon footprint of treating patients with septic shock in the intensive care unit.
McGain F, Burnham JP, Lau R, Aye L, Kollef MH, McAlister S
Crit Care Resusc. 2018 Dec; 20(4)304-312.

PMID:
    30482138
    [PubMed - indexed for MEDLINE]
Related citations


Re-estimating annual deaths due to multidrug-resistant organism infections.
Burnham JP, Olsen MA, Kollef MH
Infect Control Hosp Epidemiol. 2019 Jan; 40(1)112-113. doi: 10.1017/ice.2018.304.

PMID:
    30463634
    [PubMed - in process]
Related citations


Is Zero Ventilator-Associated Pneumonia Achievable?: Practical Approaches to Ventilator-Associated Pneumonia Prevention.
Vazquez Guillamet C, Kollef MH
Clin Chest Med. 2018 Dec; 39(4)809-822. doi: 10.1016/j.ccm.2018.08.004.

PMID:
    30390751
    [PubMed - indexed for MEDLINE]
Related citations


Protocol for a multicentre, prospective cohort study of practice patterns and clinical outcomes associated with emergency department sedation for mechanically ventilated patients: the ED-SED Study.
Fuller BM, Mohr NM, Roberts BW, Carpenter CR, Kollef MH, Avidan MS
BMJ Open. 2018 Oct 21; 8(10)e023423. doi: 10.1136/bmjopen-2018-023423.

PMID:
    30344178
    [PubMed - in process]
Related citations


Catheter removal and outcomes of multidrug-resistant central-line-associated bloodstream infection.
Burnham JP, Rojek RP, Kollef MH
Medicine (Baltimore). 2018 Oct; 97(42)e12782. doi: 10.1097/MD.0000000000012782.

PMID:
    30334966
    [PubMed - indexed for MEDLINE]
Related citations

Financial Disclosures

Financial Disclosures

Disclosure of Financial Interests with Industry

Washington University and its physicians and health professionals are committed to ensuring integrity and objectivity in medical decision-making. Some of our physicians and health professionals work collaboratively with pharmaceutical, medical device or other medical care related companies to develop innovative ideas and products that can improve health care delivery and clinical outcomes for patients. In some instances, our physicians and health professionals have an ownership or potential ownership interest in a commercial company; and/or are paid by a commercial company to provide advice on product design or to speak about the use of medications, devices, equipment or procedures. These payments may include: a) compensation for consulting and speaking engagements, b) equity, and/or c) royalties for products invented by our faculty. Any payments to Washington University physicians or health professionals must be based on tangible services and may not exceed fair market value for their work. In addition to disclosure on this website, physicians and health professionals earning more than $10,000 per year must disclose their corporate financial relationship in writing to patients when prescribing or using that company's products.

This physician reported the following financial interests during calendar year 2018:

Company Name: Allergan

Royalties:

Equity: No

Consulting/Advisory Board: $1 - $9,999

Speaker Fees: $40,000 - $59,999

Reporting Date: May 01, 2019


Company Name: Merck

Royalties:

Equity: No

Consulting/Advisory Board: $1 - $9,999

Speaker Fees: $40,000 - $59,999

Reporting Date: May 01, 2019


Company Name: Shinogi

Royalties:

Equity: No

Consulting/Advisory Board: $20,000 - $39,999

Speaker Fees:

Reporting Date: May 01, 2019